A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions — FPEB  

Parkinson Disease Clinical Trial

Official title: Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions

Status Completed

Clinical Trial Summary

Measurement of metabotropic glutamate receptor type 5 (mGluR5) binding capacity in the brain, may be a valuable tool in the early detection, understanding, or evaluation of Parkinson disease (PD), Huntington disease (HD), Fragile X syndrome (FXS), Autism Spectrum Disorder(ASD), Alzheimer's Disease(AD), and subjects with mild cognitive impairment (MCI).

The goal of this study is to assess [18F]F-PEB positron emission tomography (PET) imaging as a tool to detect mGluR5 density in the brain of PD, HD, FXS ASD, AD, and MCI research participants and similarly aged healthy subjects.

Clinical Trial Description

Informed consent will be obtained for all subjects. All subjects will undergo a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations. All subjects will undergo [18F]F-PEB PET imaging. Subjects may also be asked to undergo standard brain MRI to assist in the analysis of the PET images obtained. ;

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Alzheimer Disease
• Autism Spectrum Disorder
• Autistic Disorder
• Autistic Spectrum Disorders
• Child Development Disorders, Pervasive
• Cognition Disorders
• Fragile X Syndrome
• Huntington Disease
• Mild Cognitive Impairment
• Parkinson Disease

• NCT number: NCT00870974
• Study type: Interventional
• Source: Institute for Neurodegenerative Disorders
• Status: Completed
• Phase: Phase 1
• Start date: March 2009
• Completion date: November 2016